ClinicalTrials.gov
ClinicalTrials.gov Menu

Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00301912
Recruitment Status : Withdrawn (Withdrawn because study never opened to accrual)
First Posted : March 13, 2006
Last Update Posted : October 2, 2012
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by:
University of California, San Francisco

Brief Summary:

RATIONALE: Drugs used in chemotherapy, such as busulfan and fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy with a peripheral stem cell or bone marrow transplant may allow more chemotherapy to be given so that more cancer cells are killed. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Tacrolimus and methotrexate may stop this from happening.

PURPOSE: This phase II trial is studying how well giving busulfan together with fludarabine before donor stem cell transplant works in treating patients with hematologic cancer.


Condition or disease Intervention/treatment Phase
Anemia Chronic Myeloproliferative Disorders Leukemia Lymphoma Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Diseases Biological: filgrastim Drug: busulfan Drug: fludarabine phosphate Drug: methotrexate Drug: tacrolimus Procedure: allogeneic bone marrow transplantation Procedure: allogeneic hematopoietic stem cell transplantation Procedure: peripheral blood stem cell transplantation Phase 2

Detailed Description:

OBJECTIVES:

Primary

  • Determine the safety, in terms of treatment-related mortality at 100 days post-transplantation, of a myeloablative preparative regimen comprising busulfan and fludarabine and graft-vs-host disease (GVHD) prophylaxis comprising tacrolimus and methotrexate in patients with hematopoietic disorders undergoing matched unrelated donor stem cell transplantation.
  • Determine the efficacy, in terms of overall survival at 1-year post-transplantation, in patients treated with this regimen.

Secondary

  • Determine organ toxicity in patients treated with this regimen.
  • Determine neutrophil and platelet recovery in patients treated with this regimen.
  • Determine the incidence and severity of acute and chronic GVHD in patients treated with this regimen.

OUTLINE:

  • Myeloablative preparative regimen: Patients receive busulfan IV over 2 hours every 6 hours on days -7 to -4 and fludarabine IV over 30 minutes on days -7 to -3.
  • Allogeneic stem cell transplantation: Patients undergo allogeneic peripheral blood stem cell or bone marrow transplantation on day 0. Patients also receive filgrastim (G-CSF) subcutaneously daily beginning on day 7 and continuing until blood counts recover.
  • Graft-vs-host disease prophylaxis: Patients receive tacrolimus IV continuously beginning on day -2 and continuing until discharged from the hospital (may convert to oral dosing administered twice daily when tolerated) and methotrexate IV over 15-30 minutes on days 1, 3, 6, and 11.

After completion of study therapy, patients are followed periodically.

PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study.


Study Type : Interventional
Actual Enrollment : 0 participants
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing Matched Unrelated Donor Stem Cell Transplantation
Study Start Date : January 2002
Actual Primary Completion Date : November 2007





Primary Outcome Measures :
  1. Treatment-related mortality in the first 100 days post-transplant
  2. Overall survival at 1 year post-transplant

Secondary Outcome Measures :
  1. Incidence and severity of organ-specific toxicity
  2. Engraftment including neutrophil and platelet recovery and donor chimerism at 3 and 12 months post-transplant
  3. Rate of acute graft-vs-host disease (GVHD)
  4. Rate of chronic GVHD


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   16 Years to 60 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Diagnosis of 1 of the following hematopoietic disorders:

    • Chronic myelogenous leukemia (CML), meeting 1 of the following criteria:

      • Chronic phase disease failing imatinib mesylate therapy

        • Progressive disease OR failed to achieve a major cytogenetic response at 1 year after initiation of therapy
      • Accelerated phase disease, meeting 1 of the following criteria:

        • Failed to achieve complete cytogenetic remission at 1 year after initiation of therapy
        • Failed to achieve any cytogenetic response at 3 or 6 months during therapy
        • Progressive disease, demonstrated by worsening cytogenetic response in 2 consecutive analyses separated by 4 weeks
      • Blast crisis with < 10% blasts in bone marrow within 6 weeks of transplantation
    • Acute myeloid leukemia (AML), meeting 1 of the following criteria:

      • In second or greater remission
      • In first remission with poor prognosis cytogenetics [-5, -5q, -7, -7q and ≥ 2 cytogenetic abnormalities, t(6,9), t(9,11), or Philadelphia chromosome]
      • In hematologic remission but with persistent cytogenetic abnormalities
      • Primary refractory AML with < 10% blasts in bone marrow within 6 weeks of transplantation
    • Myelodysplasia with < 20% blasts in bone marrow within 6 weeks of transplantation and meeting 1 of the following criteria:

      • Advanced disease (International Prognostic Scoring System [IPSS] score intermediate-1, intermediate-2, or high risk)
      • Myelodysplastic syndromes (MDS) with progression to AML
      • Treatment-related AML
    • Acute lymphocytic leukemia (ALL), meeting 1 of the following criteria:

      • In second or greater remission
      • In first remission with high-risk cytogenetics [Philadelphia chromosome; t(4,11); and -7]
      • Primary refractory ALL with < 10% blasts in the bone marrow
    • Severe aplastic anemia that has failed immunosuppressive therapy
    • Non-Hodgkin's lymphoma, meeting 1 of the following criteria:

      • In second or greater remission
      • Relapsed disease in a patient not eligible for autologous stem cell transplantation
    • Lymphoproliferative disease (e.g., chronic lymphocytic leukemia or Waldenstrom's macroglobulinemia), meeting 1 of the following criteria:

      • In second or greater remission
      • Relapsed disease in a patient not eligible for autologous stem cell transplantation
    • Multiple myeloma, meeting 1 of the following criteria:

      • Stage II or III disease in first or greater relapse
      • Refractory disease
      • Newly diagnosed disease with chromosome 13 abnormalities
    • Advanced myeloproliferative disease, meeting 1 of the following criteria:

      • Myelofibrosis requiring > 2 units of packed red blood cells each month
      • Essential thrombocythemia or polycythemia rubra vera that has progressed to AML
      • Failed prior AML therapy
  • No active, uncontrolled CNS leukemia
  • Not eligible for autologous or mini-allogeneic transplantation
  • No fully matched or single-antigen mismatched sibling donor available
  • HLA-matched unrelated donor available

    • HLA typed at HLA-A, -B, -C, -DRB1 and/or -DQB1 by high-resolution techniques
    • For patients without HLA identical donors, mismatches at DQ (i.e., 8/8 match) and 1 additional mismatch at the allele level at HLA-A, -B, -C, or -DRB1 (i.e., 7/8 molecular match) allowed

PATIENT CHARACTERISTICS:

  • ECOG performance status 0-2
  • Creatinine < 2.0 mg/dL
  • Pulmonary diffusing capacity > 40% of predicted
  • Cardiac ejection fraction > 40% by MUGA or echocardiography
  • No active liver disease
  • Bilirubin ≤ 2.0 mg/dL
  • Alkaline phosphatase < 3 times upper limit of normal (ULN)
  • AST < 3 times ULN
  • Hepatitis C or active hepatitis B (HBV) allowed provided a liver biopsy is performed and ≤ grade 2 inflammation is present

    • Patients with active HBV viral replication must receive antiviral therapy
  • HIV negative
  • No ongoing active infection
  • Not pregnant or nursing
  • Negative pregnancy test

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • More than 3 weeks since prior chemotherapy except for hydroxyurea or imatinib mesylate
  • More than 3 months since prior interferon

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00301912


Locations
United States, California
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States, 94115
Sponsors and Collaborators
University of California, San Francisco
National Cancer Institute (NCI)
Investigators
Study Chair: Thomas G. Martin, MD University of California, San Francisco

Responsible Party: Thomas G. Martin, III, UCSF Helen Diller Family Comprehensive Cancer Center
ClinicalTrials.gov Identifier: NCT00301912     History of Changes
Other Study ID Numbers: CDR0000463168
UCSF-02257
UCSF-2214
UCSF-H24045-22163-04
First Posted: March 13, 2006    Key Record Dates
Last Update Posted: October 2, 2012
Last Verified: October 2012

Keywords provided by University of California, San Francisco:
adult acute myeloid leukemia in remission
adult acute myeloid leukemia with 11q23 (MLL) abnormalities
adult acute myeloid leukemia with inv(16)(p13;q22)
adult acute myeloid leukemia with t(15;17)(q22;q12)
adult acute myeloid leukemia with t(16;16)(p13;q22)
adult acute myeloid leukemia with t(8;21)(q22;q22)
recurrent adult acute myeloid leukemia
adult acute lymphoblastic leukemia in remission
recurrent adult lymphoblastic lymphoma
extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
nodal marginal zone B-cell lymphoma
recurrent adult Burkitt lymphoma
recurrent adult diffuse large cell lymphoma
recurrent adult diffuse mixed cell lymphoma
recurrent adult immunoblastic large cell lymphoma
recurrent mantle cell lymphoma
recurrent adult diffuse small cleaved cell lymphoma
noncontiguous stage II adult Burkitt lymphoma
noncontiguous stage II adult diffuse large cell lymphoma
noncontiguous stage II adult diffuse mixed cell lymphoma
noncontiguous stage II adult diffuse small cleaved cell lymphoma
noncontiguous stage II adult immunoblastic large cell lymphoma
noncontiguous stage II adult lymphoblastic lymphoma
noncontiguous stage II mantle cell lymphoma
stage III adult Burkitt lymphoma
stage III adult diffuse large cell lymphoma
stage III adult diffuse mixed cell lymphoma
stage III adult diffuse small cleaved cell lymphoma
stage III adult immunoblastic large cell lymphoma
stage III adult lymphoblastic lymphoma

Additional relevant MeSH terms:
Neoplasms, Plasma Cell
Pathologic Processes
Lymphoma
Syndrome
Leukemia
Multiple Myeloma
Myelodysplastic Syndromes
Preleukemia
Plasmacytoma
Myeloproliferative Disorders
Myelodysplastic-Myeloproliferative Diseases
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Disease
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Bone Marrow Diseases
Precancerous Conditions
Methotrexate
Fludarabine phosphate
Tacrolimus